Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC

NCT05430386 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

174

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: HS-10241

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.